Syneos Health Inc - Class A
SYNH
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
2.3% upsideUndervalued by 2.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.46 Billion |
|---|---|
| Enterprise Value | $8.07 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.57 |
| Beta | 1.58 |
| Outstanding Shares | 103,679,000 |
Return
| Return on Equity | 2.04% |
|---|---|
| Return on Assets | 0.88% |
| Return on Invested Capital | 5.18% |
Valuation & Multiples
| P/E Ratio | 16.61 |
|---|---|
| PEG | -16.78 |
| Price to Sales | 0.83 |
| Price to Book Ratio | 1.3 |
| Enterprise Value to Revenue | 1.49 |
| Enterprise Value to EBIT | 24.15 |
| Enterprise Value to Net Income | 113 |
| Total Debt to Enterprise | 0.46 |
| Debt to Equity | 1.06 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Syneos Health Inc
23,000 employees
CEO: Alistair Macdonald Syneos Health is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer perfor...
Relevant Senate Committees
This powerful committee controls taxation, directly impacting Syneos Health's profitability. Its influence on Medicare pricing critically affects the commercial viability of therapies Syneos Health's CCO arm helps commercialize.
This committee directly regulates the FDA, impacting drug approval processes central to Syneos Health's CRO services, and oversees NIH funding, which supports biopharma research. Its labor laws also directly affect Syneos Health as a large employer.